Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
29. August 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
31. Juli 2024 16:05 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering to Present at the Jefferies Global Healthcare Conference
29. Mai 2024 16:05 ET
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07. Mai 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Recognizes Melanoma Awareness Month
06. Mai 2024 16:30 ET
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27. März 2024 08:00 ET
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04. März 2024 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
06. März 2023 16:05 ET
|
Immuneering Corporation
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05. März 2023 18:30 ET
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
The RAS targeting therapies market is anticipated to grow at an annualized rate of over 50%, till 2031, claims Roots Analysis
14. Oktober 2021 09:45 ET
|
Roots Analysis
London, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “RAS Targeting Therapies Market, 2021-2031” report to its list of offerings. Growing research activity in...